<SEC-DOCUMENT>0001193125-25-080833.txt : 20250415
<SEC-HEADER>0001193125-25-080833.hdr.sgml : 20250415
<ACCEPTANCE-DATETIME>20250415083246
ACCESSION NUMBER:		0001193125-25-080833
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250415
DATE AS OF CHANGE:		20250415

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276774
		FILM NUMBER:		25837697

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d941634d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-276774</FONT></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
December&nbsp;2, 2024) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>475,555 American Depositary Shares representing </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>47,555,560 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary
Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g941634g0412034427235.jpg" ALT="LOGO" STYLE="width:2.25139in;height:0.645833in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December&nbsp;2, 2024 (the
&#147;Prospectus&#148;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-276774),</FONT> with the information contained in our current
report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the Securities and Exchange Commission on April&nbsp;15, 2025 (the &#147;April 15, 2025 Form <FONT STYLE="white-space:nowrap">6-K&#148;).</FONT> Accordingly, we have attached
the April&nbsp;15, 2025 Form <FONT STYLE="white-space:nowrap">6-K</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates and
supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in
conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#147;Nasdaq&#148;) under the symbol &#147;KZIA.&#148; On April&nbsp;14, 2025, the last reported sale price
of the ADSs on Nasdaq was $0.7893 per ADS. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page 9 of the Prospectus and the &#147;Risk
Factors&#148; in &#147;Item 3. Key Information&#151;D. Risk Factors&#148; of our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> which is incorporated by reference in the Prospectus, as well as in any other recently
filed reports and, if any, in any applicable prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is April&nbsp;15, 2025 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">6-K</FONT></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of April, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (the &#147;Company&#148;) plans to change the ratio of its American Depositary Shares (&#147;ADSs&#148;)
to Ordinary Shares from one (1)&nbsp;ADS representing one hundred (100)&nbsp;Ordinary Shares to one (1)&nbsp;ADS representing five hundred (500)&nbsp;Ordinary Shares (the &#147;ADS Ratio Change&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADS Ratio Change will have the same effect as a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-five</FONT></FONT> reverse ADS split for our ADS holders. There will be no change to our underlying Ordinary Shares, and no Ordinary Shares will be issued or cancelled in
connection with the ADS Ratio Change. The effect of the ratio change on the ADS trading price on the Nasdaq Capital Market is expected to take place at the opening of business on April&nbsp;17, 2025. Following the ADS Ratio Change, our ADSs will
continue to be traded on the Nasdaq Capital Market under the ticker symbol &#147;KZIA.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional new ADSs will be issued in
connection with the ADS Ratio Change. Instead, fractional entitlements to the new ADSs will be aggregated and sold by the depositary bank, and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes,
and expenses) will be distributed to the applicable ADS holders by the depositary bank. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the ADS Ratio Change, the ADS
price is expected to increase proportionally, although the Company can give no assurance that the ADS price after the ADS Ratio Change will be equal to or greater than five times the ADS price before the ADS Ratio Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date hereof, the Company has an aggregate of 6,798,129 ADSs issued and outstanding. Immediately following the ADS Ratio Change, the
Company will have an aggregate of 1,359,625 ADSs issued and outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Board of Directors approved the ADS Ratio
Change with the objective of maintaining compliance with the minimum bid price of $1.00 per share as outlined in the Nasdaq Listing Rules. The Company can give no assurance that this event will result in the Company maintaining compliance with
Nasdaq&#146;s minimum bid price requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein into the
Company&#146;s registration statements on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-276091</FONT> and <FONT STYLE="white-space:nowrap">333-281937).</FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain
statements in this Report on Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">6-K-</FONT></FONT> that are forward-looking and not statements of historical fact are forward-looking statements, which can generally be identified
as such by the use of words such as &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any statement describing Kazia&#146;s future plans, strategies,
intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forwardlooking statements, including, but not limited to, statements regarding: the timing for results and data related to
Kazia&#146;s clinical and preclinical trials, Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801, the potential benefits of paxalisib as an investigational PI3K/mTOR inhibitor, timing for any regulatory
submissions or discussions with regulatory agencies, the potential market opportunity for paxalisib, and the ADS Ratio Change. Such statements are based on Kazia&#146;s current expectations and projections about future events and future trends
affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and
preclinical trials and product development, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia&#146;s Annual Report, filed on form <FONT
STYLE="white-space:nowrap">20-F</FONT> with the United States Securities and Exchange Commission (the &#147;SEC&#148;), and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether
as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this report. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited </B>(Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 15&nbsp;April 2025</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g941634g0412034427235.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g941634g0412034427235.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] -4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W;: !@=*I
M:IJ/]F6#S^7N.0%!]3ZT_4Y9HM,GD@ ,BK\N/UK&T":YU-+B'4%:6' QO'>M
M*=-<O,]ET.6K6:G[..[6CZ(6'4+G6M&NO)C\NY3"_*>#]#VXIOAZRU&WMKI9
M=T:NN(U8\[N>:M76HZ3X?*6[D1B0Y"J/PR:I>(?%+Z1=VZ00B5)(]^X]QZ"E
M+$1BG&*TN:4L#4J.,Y7YM?),9H-CJ=MJ$LEPK+'M)DR<ASZBK6G^(FNM6^RM
M %1B50@\\>M6[OQ'I]D;>.[<H\RA@N,[0?6IFL+6".6\M84^T,A96 ZYJU6C
M-OF6K_ R>&J4(IINVKU_0T_J*?VKD_#E[J%S?RQW)=HPN3O['VKJ_6LYQY'8
MUHU55AS)6'44T=*\<7QYKY\?_P!EFX06G]H_9PNP9V;\?RI)-HU;L['LU%<5
MXZ\8IX7T_P JW*OJ,H_=J>=@_O&J7P\U3Q+KL4NHZK.IL2NV)=@!<_WOI1RN
MUQ<RO8]"HIJYVC/I1SNQ2*'4E>:'X@'_ (68-,\P?V7_ ,>V?^FO][\^*]+'
M2FTT)-,7M24=J\Y^('B#7]$OK*/1U<I)&Q?;%NYS^E)*[!NQZ-1FO )OB%XP
MML>?(8MWW?,AVYKT#X<:QKFOVUU?ZK,K6^X1P (!EA]X_P A5N#2N)23._HQ
M31Z5Y'XL\::[H_C233;*=4MU\K"E ?O8SS4Q38W*QZ_144#%H$8]2H)J6D,*
M0UA^*=:C\/Z!=:@S .B$1 ]W/2L?X>^)Y/$6@9NY-]];-LF_V@>0?R_E3Y7:
MXKJ]CM**%.112&<?J>JZC!K/DQ(?+# *N.&%:FM:F-'TIKM8=S9 "CID^M4;
M'7A>ZPL#VZA6)"-CD8IGB;74TQX[-[59EF7<P;ICI^=:57RQ2:MH88*'/5<K
M\R;V]"M!96OC*RCO[E'BFB)B.T\,,UTK:=:21Q)) CB$ )N&<4FG) NGPFWB
M$<;*&"@=,UQNH:U>3WTFR5D16(514X>@ZM[,UQF-]C;>UW9'0:KX:L]7NDGF
M)#(-IQW JIIGB8SZ[_97V8K$I,:'N,<<UI^'+^6_T[=,<R1G:3ZUBZYK5OHF
MNIY5BC32*&>3')S6,X.G)^IT4JOMX)-7TT\C0U^[NK$0BT!029W.JUJZ5/-<
M:;!+<KME9>14.J7XL]+%UY0<'&%8=,U'H6IMJELSR1A6C;''0UT-.4-MCSHI
M0K<KENMC:':OFC4;S^SOB#>7VW?]GU%Y0OKA\U]+BOG QI/\47AD4-&^K,K*
M>X,F**?4WGT+.A6<_C[QNS:A< *Q,L@SSM'\*U[]:VT-I:QV]NBQQ1J%15'
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0M%)10,6BDHH 6BDHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
